In August 2018 Renovia Inc. moved to close a deal worth $32 million Series B and $10 million in venture debt. This move would see the company come up with new pharmaceutical products for pelvic floor disorders. Renovia Inc. is a start-up company based in Boston that was co-founded by Marc Beer, the former CEO of Aegerion Pharmaceuticals. The MedTech Company strives to come up with different diagnostic and therapeutic products to provide treatment for pelvic disorder disorders such as urinary incontinence. According to research, more than 250 million women in the world are affected by these disorders.
A healthcare- focused investing company by the name The Loongwood Fund and also the early investors in Renovia became part of the Series B round. The funding brought in will to go a long way towards the development and testing of more therapeutic and diagnostic products as well as a new form of Leva. Renovi’s CEO Marc Beer was glad to point out that they are thrilled to have THE support from the Longwood investment company. Together, they believe they will drastically change the lives of women whose lives have been affected by the pelvic floor disorders.
With more than 25 years of experience in the development and commercialization of pharmaceuticals, diagnostics, devices, and biotechnology, Marc was able to clinch the CEO’s position at Renovia. Before co-founding Renovia with Ramon Iglesias, Marc worked with a number of biopharmaceutical organizations in both leadership positions and other positions. Under his leadership, he has assisted various companies to go public. He has also enabled different pharmaceutical companies to launch their first products and even get FDA approval.
Marc worked as the founding CEO of ViaCell, a biotechnology company focusing on the development, collection, and preservation of the umbilical cord blood system. During his tenure, the company grew from a start-up to a robust company with over 300 employees. He enabled the company to go public and was eventually acquired by PerkinElmer in 2007. While still working at ViaCell, Marc also worked as a board member of the directors of Erytech Pharma, which is a biopharmaceutical company that trades publicly.
Marc served in different positions while at Genzyme before he set foot at ViaCell. He also held different sales and marketing roles in pharmaceutical and diagnostic divisions of Abbott Laboratories. He was once a member of the Mass Life Science Board of the Commonwealth of Massachusetts. Learn more: https://www.cnbc.com/video/2013/01/23/aegerion-ceo-on-promise-of-biopharma.html